Annuncio • Jun 10
Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares. Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with Samsung Securities. The purpose of the program is to enhance shareholder value. The program will expire on September 9, 2026. As of June 8, 2026, the company had 103,046 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase. Buy Or Sell Opportunity • Jun 09
Now 28% overvalued Over the last 90 days, the stock has fallen 29% to ₩26,200. The fair value is estimated to be ₩20,534, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Upcoming Dividend • May 19
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 26 May 2026. Payment date: 15 June 2026. Trailing yield: 2.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.9%). New Risk • Apr 23
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Mar 26
Upcoming dividend of ₩200 per share Eligible shareholders must have bought the stock before 02 April 2026. Payment date: 22 April 2026. Trailing yield: 1.8%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%). Annuncio • Mar 17
Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026 Humedix Co., Ltd., Annual General Meeting, Mar 31, 2026, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea Major Estimate Revision • Feb 21
Consensus EPS estimates increase by 16% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩4,334 to ₩5,018. Revenue forecast unchanged at ₩171.5m. Net income forecast to grow 112% next year vs 13% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩61,000 unchanged from last update. Share price rose 3.2% to ₩43,250 over the past week. Price Target Changed • Dec 03
Price target increased by 13% to ₩61,000 Up from ₩54,000, the current price target is an average from 2 analysts. New target price is 37% above last closing price of ₩44,650. Stock is up 36% over the past year. The company posted earnings per share of ₩964 last year. Upcoming Dividend • Nov 17
Upcoming dividend of ₩570 per share Eligible shareholders must have bought the stock before 24 November 2025. Payment date: 11 December 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.7%). Higher than average of industry peers (0.8%). New Risk • Sep 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Aug 16
Upcoming dividend of ₩150 per share Eligible shareholders must have bought the stock before 20 August 2025. Payment date: 05 September 2025. Trailing yield: 1.1%. Lower than top quartile of South Korean dividend payers (3.6%). In line with average of industry peers (1.0%). New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Upcoming Dividend • Jun 20
Upcoming dividend of ₩300 per share Eligible shareholders must have bought the stock before 27 June 2025. Payment date: 22 August 2025. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.0%). Major Estimate Revision • May 21
Consensus EPS estimates increase by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from ₩186.9m to ₩192.7m. EPS estimate increased from ₩4,121 to ₩4,766 per share. Net income forecast to grow 112% next year vs 21% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target up from ₩54,000 to ₩56,500. Share price rose 20% to ₩51,200 over the past week. New Risk • May 20
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company. Annuncio • May 08
Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 5,000 million worth of its shares. Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a contract with SAMSUNG SECURITIES Co., Ltd. The purpose of the program is to improve shareholder value. The program will expire on November 7, 2025. As of May 6, 2025, the company had 885,401 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase. New Risk • Apr 16
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Upcoming Dividend • Mar 21
Upcoming dividend of ₩330 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 24 April 2025. Trailing yield: 1.3%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%). Annuncio • Mar 13
Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025 Humedix Co., Ltd., Annual General Meeting, Mar 26, 2025, at 11:30 Tokyo Standard Time. Location: auditorium, 17, changeop-ro, sujeong-gu, gyeonggi-do, seongnam South Korea Annuncio • May 25
Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares. Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 26, 2024. As of May 23, 2024, the company had 810,507 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase. Price Target Changed • Apr 14
Price target increased by 17% to ₩56,000 Up from ₩48,000, the current price target is provided by 1 analyst. New target price is 70% above last closing price of ₩32,850. Stock is up 32% over the past year. The company posted earnings per share of ₩964 last year. Upcoming Dividend • Mar 22
Upcoming dividend of ₩275 per share Eligible shareholders must have bought the stock before 29 March 2024. Payment date: 19 April 2024. Trailing yield: 1.9%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%). Price Target Changed • Jan 19
Price target decreased by 15% to ₩56,000 Down from ₩66,000, the current price target is provided by 1 analyst. New target price is 79% above last closing price of ₩31,300. Stock is up 7.6% over the past year. The company posted earnings per share of ₩964 last year. Major Estimate Revision • Nov 15
Consensus EPS estimates fall by 11%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from ₩157.0m to ₩160.0m. EPS estimate fell from ₩3,390 to ₩3,008 per share. Net income forecast to grow 135% next year vs 30% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target of ₩66,000 unchanged from last update. Share price fell 6.8% to ₩34,000 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 24 April 2023. Trailing yield: 1.5%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Annuncio • Sep 28
Humedix Co., Ltd. (KOSDAQ:A200670) announces an Equity Buyback for KRW 3,000 million worth of its shares. Humedix Co., Ltd. (KOSDAQ:A200670) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with Samsung Securities Co., Ltd.. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on March 27, 2023. As of March 15, 2022, the company had 680,117 shares in treasury within scope available for dividend and had 24,411 shares in treasury through other repurchase. Annuncio • Jun 24
An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion. An unknown buyer agreed to acquire a 22.3% stake in Huons Meditech from Humedix Co., Ltd. (KOSDAQ:A200670) for KRW 21.5 billion on June 22, 2022. The transaction is resolved by the board of Humedix and expected to complete on June 30, 2022. Buying Opportunity • Mar 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years. Buying Opportunity • Feb 14
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 21%. The fair value is estimated to be ₩26,400, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% per annum over the last 3 years. Earnings per share has grown by 22% per annum over the last 3 years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩400 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improved over the past week After last week's 16% share price gain to ₩38,700, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 33% over the past three years. Reported Earnings • May 12
First quarter 2021 earnings released: EPS ₩330 (vs ₩99.00 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩28.4b (up 48% from 1Q 2020). Net income: ₩3.11b (up 215% from 1Q 2020). Profit margin: 11% (up from 5.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 18% share price gain to ₩38,850, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improved over the past week After last week's 40% share price gain to ₩35,750, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 4.6% over the past three years. Annuncio • Apr 07
Humedix Co., Ltd. announced that it has received KRW 45 billion in funding from a group of investors On April 6, 2021, Humedix Co., Ltd. (KOSDAQ:A200670) closed the transaction. Reported Earnings • Mar 14
Full year 2020 earnings released: EPS ₩1,587 (vs ₩1,094 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩98.5b (up 25% from FY 2019). Net income: ₩15.1b (up 45% from FY 2019). Profit margin: 15% (up from 13% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Feb 20
New 90-day high: ₩26,050 The company is up 5.0% from its price of ₩24,800 on 20 November 2020. The South Korean market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improved over the past week After last week's 19% share price gain to ₩26,050, the stock is trading at a trailing P/E ratio of 21.9x, up from the previous P/E ratio of 18.4x. This compares to an average P/E of 28x in the Pharmaceuticals industry in South Korea. Total return to shareholders over the past three years is a loss of 31%. Is New 90 Day High Low • Jan 18
New 90-day low: ₩21,250 The company is down 12% from its price of ₩24,050 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩400 Per Share Will be paid on the 17th of April to those who are registered shareholders by the 29th of December. The trailing yield of 2.1% is below the top quartile of South Korean dividend payers (2.6%), but it is higher than industry peers (0.6%). Is New 90 Day High Low • Oct 23
New 90-day low: ₩23,500 The company is down 17% from its price of ₩28,450 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Sep 24
New 90-day low: ₩24,050 The company is down 6.0% from its price of ₩25,500 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 23% over the same period.